PDL BioPharma Inc

PDL BioPharma — Cowen 39th Annual Healthcare Conference (March 2019)

28 slides from PDL BioPharma's conference presentation, Mar 12, 2019

  1. Slide 1: Cowen 39th Annual Healthcare Conference

    Slide 1: Cowen 39th Annual Healthcare Conference

    PDL Cowen 39 Annual Healthcare Conference March 12, 2019 PDL BioPharma, Inc. Nasdaq: PDLI

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: PDL's Evolving Strategy

    Slide 3: PDL's Evolving Strategy

    PDL’s Evolving Strategy Maximize shareholder value through the acquisition, nurturing and growth of a portfolio of healthcare assets. Strategic focus on developing and capturing the value of a portfolio of actively managed operating companies with revenue growth potential: + Noden Pharma DAC, a spec

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights Noden Pharma - Focus on generating profitable cash flows with Tekturna®/ Rasilez®, maximizing well-targeted international market opportunities and mitigating impact of anticipated generic competition in U.S. LENSAR serves the world’s highest-volume surgical procedure with marke

  5. Slide 5: Business Development Strategy

    Slide 5: Business Development Strategy

    Business Development Strategy What we are looking for: * Commercial-stage products and/or companies which performance may be improved through access to PDL’s capital and expertise. + Late development stage assets or pre-commercialization products. + Products or companies that present synergies with

  6. Slide 6: Leadership with Proven Track Record

    Slide 6: Leadership with Proven Track Record

    Leadership with Proven Track Record Executive Management Dominique Monnet, President & CEO Peter Garcia, CFO Chris Stone, General Counsel Jill Jene, Ph.D., VP, Business Dev. Alan Markey, CEO, Noden Pharma Nick Curtis, CEO, LENSAR Capabilities & Accomplishments Over $1 billion in completed transactio

  7. Slide 7: Noden Pharma

    Slide 7: Noden Pharma

    PDL NODEN y PHARMA

  8. Slide 8: The Noden/Tekturna Transaction

    Slide 8: The Noden/Tekturna Transaction

    The Noden/Tekturna® Transaction + Noden Pharma and Tekturna®/Rasilez® were PDL’s first operational acquisitions in July 2016. + Strategic rationale: — Build a global, nimble commercial platform around a differentiated but neglected, niche cardiovascular product. — The transaction terms were hedged t

  9. Slide 9: The Tekturna Opportunity

    Slide 9: The Tekturna Opportunity

    The Tekturna® Opportunity * Hypertension is a chronic condition with serious long-term health implications, affecting nearly 50% of all adults in the U.S. * Angiotensin Converting Enzyme Inhibitors (ACEls) and Angiotensin Il Receptor Blockers (ARBs) are typically first- and second-line therapies. *

  10. Slide 10: Tekturna Impact of Settlement with Anchen

    Slide 10: Tekturna Impact of Settlement with Anchen

    40 Tekturna® Impact of Settlement with Anchen Paragraph IV filing in April 2017 by Anchen Pharmaceuticals regarding Tekturna® directed to the formulation patent expiring in 2026, but not to the API based patents that expire in January 2019 (Tekturna®, with pediatric extension). Anchen agreed not to

  11. Slide 11: Noden U.S.: Focus on Profitability

    Slide 11: Noden U.S.: Focus on Profitability

    " Noden U.S.: Focus on Profitability Actions to increase the profitability of Tekturna® and mitigate the impact of potential generic competition include: - Discontinued contract sales force in August 2018; o Resulting in sales and marketing expenses savings of $3.5 to $4 million per quarter. - Trans

  12. Slide 12: Tekturna NRx Volume Has Remained Stable Since Elimination of Field Force

    Slide 12: Tekturna NRx Volume Has Remained Stable Since Elimination of Field Force

    Tekturna® NRx Volume Has Remained Stable Since Elimination of Field Force Tekturna® NRx 2/16/18 — 2/15/19 4,400 4,200 4,000 800 Field Sales 600 NPP Program 400 200 2 2 2 KS 12 @ 2 K 3 sm 1 2 & F&F FF EF KF EF SF SF KF SF SE es s 3 ex 3 gt a , x — National NRx IMS Xponent Weekly NRx 2/16/18 — 2/15/19

  13. Slide 13: Maximizing Rasilez Profitability Ex-U.S.

    Slide 13: Maximizing Rasilez Profitability Ex-U.S.

    Maximizing Rasilez® Profitability Ex-U.S. Reviewed each ex-U.S. market and determined to: — Make no investments in direct promotions. — De-register the products in unprofitable markets. - Identify and pursue growth geographies. Actions: — EU: Nov. 2017 assumed commercialization in the EU and Switzer

  14. Slide 14: The Noden Transaction Report

    Slide 14: The Noden Transaction Report

    The Noden Transaction Report + Noden Pharma and Tekturna ®/Rasilez® were PDL’s first operational acquisitions. - Turning around a previously neglected, rapidly declining product has proven more challenging than expected; hence the evolution of our strategy to the acquisition of earlier stage assets

  15. Slide 15: LENSAR

    Slide 15: LENSAR

    PDL CATARACT LASER WITH AUGMENTED REALTY

  16. Slide 16: LENSAR

    Slide 16: LENSAR

    18 | LENSAR Converted debt to equity in May 2017. - Ability to utilize $116.5 million in NOLs. - PDLutilized approximately $31.4 million in LENSAR NOLs in 2017 resulting in cash tax savings of approximately $11 million. - Consider an exit when shareholder value is maximized. Global developer and man

  17. Slide 17: LENSAR Highlights

    Slide 17: LENSAR Highlights

    LENSAR Highlights >27 million cataract surgeries estimated in 2018. Integrating preop diagnostics is driving growth by improving efficiencies and delivering better outcomes. Existing treatments are sub-optimal for managing astigmatism (60-70% of cataract patients). ‘eth Widely recognized as the tech

  18. Slide 18: LENSAR Evolution: Continued Innovation

    Slide 18: LENSAR Evolution: Continued Innovation

    LENSAR Evolution: Continued Innovation IF YOUR FEMTOSECOND CATARACT LASER HASN'T EVOLVED, IT’S PROBABLY EXTINCT ; ~li NEW \ AR NY, Don't let your technology put you at risk for ‘extinction. Manage astigmatism with LENSAR®, now with Streamline? IV. Join the Evolution. [LEARN MORE>

  19. Slide 19: Royalty and Debt Portfolio

    Slide 19: Royalty and Debt Portfolio

    PDL Royalty and Debt Portfolio

  20. Slide 20: Royalty and Debt Deals as Sources of Cash

    Slide 20: Royalty and Debt Deals as Sources of Cash

    Royalty and Debt Deals as Sources of Cash Royalty Transaction ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition 3K Depomed 24,500,000 Ostoberz0"2 $20,000000 July 2018 Financing A | LENSAR $60,000,000 October 2013, ‘Senior Secured inancing Oo DURATA $

  21. Slide 21: Cash Flow Funds the New Business Strategy

    Slide 21: Cash Flow Funds the New Business Strategy

    Cash Flow Funds the New Business Strategy: $57 million of Cash Royalties YTD Q3-2018 Cerdelga’ (eliglustat) capsules ZAM J kybella Asserno= FNTSTRIA indefinite Asserrics MERCK, 6/2018 ioe (q) uebinges ] names Wigs, L0G, 5/2026 _ $260.5MM mm, Assernos yanssen J 9/2023 aaa peed Lu, 12/2026 | = S Payof

  22. Slide 22: Projected Cash Flows from Royalties

    Slide 22: Projected Cash Flows from Royalties

    22 Projected Cash Flows from Royalties 2018 to 2023 Cumulative cash flows expected to exceed $400 million $90 $450 $80 $400 $70 $350 $60 $300 $50 $250 $30 $150 ‘Annual Cash Royalties ($ millions) Cumulative Cash Royalties ($ millions) 2018 2019 2020 2021 2022 2023 Year mm Assertio/Depomed mam U of M

  23. Slide 23: Financials

    Slide 23: Financials

    PDL Financials

  24. Slide 24: Third Quarter 2018 Financials

    Slide 24: Third Quarter 2018 Financials

    Third Quarter 2018 Financials Three Months Ended Nine Months Ended ji September 30, September 30, Key Points (In thousands, except per share amounts) 2018 2017 2018 2017 + Q3 2018 revenue of Royalties from Queen et al. patents $533 § 1443 _$ 4534 $31,884 Royalty rights - change in fair value 42,184

  25. Slide 25: Strong Balance Sheet

    Slide 25: Strong Balance Sheet

    Strong Balance Sheet September 30, 201 Cash, cash equivalents and short-term investments $401 Total Assets $984 Debt: 2.75% Convertible Debt — due 12/2021 ($3.81 conversion price)’ $150 1) PDLentered into a capped call transaction to offset potential dilution subject to a cap of $4.88.

  26. Slide 26: Current Share Price ~70% of Book Value

    Slide 26: Current Share Price ~70% of Book Value

    26 Current Share Price ~70% of Book Value PDL’s book value per share for the period ending September 30, 2018 was $5.07 PDL's Book Value Per Share RSASRSASRSaShSa SSSPREENNNNUWWW REREAD Roa Pyeyspenspeyspepsrerspays asa 4 4 4 4 Ss 5 5 5 6 16 6 6 7 7 7 7 8 8 8 Sep-13 3 & Mar Does not include asset va

  27. Slide 27: Share Repurchase Program

    Slide 27: Share Repurchase Program

    27 Share Repurchase Program While our focus is on the strategic acquisition of biopharma assets, given the significant discount of PDL’s stock price to its book value, we have implemented share repurchase programs to return value to shareholders. Announced a new $100 million share repurchase program

  28. Slide 28: Why Invest in PDLI?

    Slide 28: Why Invest in PDLI?

    Why Invest in PDLI? Upside from the new business model Strong cash flow generation Significantly undervalued Committed to creating shareholder value and closing the valuation gap

Source: SEC EDGAR · 8-K filed Mar 12, 2019

More decks from PDL BioPharma Inc